Last updated: October 15, 2026
Actelion Pharmaceuticals Ltd. sued Mylan Pharmaceuticals Inc. in the District of Delaware under the Hatch-Waxman Act over Mylan’s abbreviated new drug application for generic selexipag, the active ingredient in Uptravi. The case concerned Actelion’s selexipag patent estate, including U.S. Patent Nos. 8,598,227 and 9,273,047. The dispute ended without a trial or merits judgment after the parties resolved the case and the action was dismissed. The public record does not establish an immediate generic launch date.
What drug was involved in Actelion v. Mylan?
The case involved selexipag tablets, marketed by Actelion as Uptravi for pulmonary arterial hypertension.
| Item |
Information |
| Brand |
Uptravi |
| Active ingredient |
Selexipag |
| Therapeutic category |
Pulmonary arterial hypertension |
| Dosage form |
Oral tablets |
| Regulatory pathway |
Mylan ANDA under 21 U.S.C. § 355(j) |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:20-cv-00110 |
| Judge |
Richard G. Andrews |
| Filing period |
January 2020 |
| Disposition |
Resolved and dismissed without a merits trial |
Uptravi is a prostacyclin-receptor agonist. Its commercial value derives from chronic use in pulmonary arterial hypertension, where it competes with endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators and other prostacyclin-pathway therapies.
What patents did Actelion assert against Mylan?
The litigation centered on Actelion’s patent rights covering selexipag and related pharmaceutical protection. The principal patents associated with the case were U.S. Patent Nos. 8,598,227 and 9,273,047.
U.S. Patent No. 8,598,227
The ’227 patent is part of Actelion’s selexipag patent portfolio. It provides protection relating to the active pharmaceutical compound and its use in treating pulmonary hypertension. Its term extends beyond the earliest selexipag compound protection and was significant to the timing of generic entry.
U.S. Patent No. 9,273,047
The ’047 patent provided additional protection for selexipag-related subject matter and supported Actelion’s Hatch-Waxman position against Mylan’s ANDA. A second asserted patent can materially affect generic launch economics because a generic applicant must overcome each patent at issue or obtain a negotiated entry right.
The litigation record should be read together with the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, and the underlying patent documents. Orange Book listing status can change as patents expire, are delisted, or become subject to regulatory updates. [FDA, 2024]
Why did Actelion sue Mylan?
Actelion filed the action after receiving notice that Mylan had submitted an ANDA seeking approval for generic selexipag tablets. Mylan’s filing was understood to include a Paragraph IV certification that the relevant Actelion patents were invalid, unenforceable or would not be infringed by Mylan’s proposed product.
A Paragraph IV certification creates a statutory patent dispute. The patent owner may sue within 45 days of receiving notice. A timely suit generally triggers a 30-month stay of FDA approval, subject to court action, patent expiration, settlement or other statutory events. [21 U.S.C. § 355(j)]
The complaint placed patent validity, infringement and claim scope at issue. The record does not show a final judicial determination that Mylan’s product infringed a valid and enforceable Actelion patent.
Was there a Paragraph IV challenge?
Yes. The case arose from Mylan’s ANDA and Paragraph IV position concerning generic selexipag. The Paragraph IV framework allowed Mylan to challenge Actelion’s patent barriers before expiration rather than waiting for the patents to lapse.
The practical consequences were:
- Actelion obtained the ability to pursue a patent injunction.
- Mylan obtained a litigation route to challenge the selexipag estate.
- FDA approval timing became linked to both the 30-month stay and the negotiated resolution.
- The parties could preserve a later launch arrangement without obtaining a court ruling on every asserted claim.
The public case disposition does not provide a merits ruling resolving the validity or infringement of the asserted patents.
What was the litigation timeline?
| Date or period |
Event |
| January 2020 |
Actelion commenced the District of Delaware action against Mylan. |
| 2020 |
The parties litigated the Hatch-Waxman claims concerning Mylan’s ANDA for generic selexipag. |
| 2020-2021 |
The case proceeded through settlement-related activity rather than a reported trial judgment. |
| 2021 |
The action was dismissed after resolution between the parties. |
| After dismissal |
The public docket did not establish a detailed commercial launch date or complete settlement terms. |
The case therefore ended as a negotiated patent dispute rather than through claim construction, summary judgment, trial or appellate review.
What was the final litigation status?
The case was dismissed after settlement. The dismissal ended the court action but did not invalidate the patents, cancel the ANDA, or create a public judicial holding on infringement.
A settlement dismissal usually leaves several commercially relevant questions unresolved in the public record:
- Whether Mylan received a license to launch before patent expiration.
- Whether launch was tied to a fixed date, a regulatory event or an earlier generic entrant.
- Whether the agreement contained supply, royalty or manufacturing provisions.
- Whether Mylan agreed to a no-challenge, delayed-launch or contingent-launch structure.
- Whether Actelion retained rights against later ANDA filers.
Because the complete settlement agreement is not part of the public merits record, the dismissal should not be interpreted as a victory for either side on patent validity.
Did the case produce a patent invalidity or infringement ruling?
No reported merits judgment establishes that the asserted Actelion patents were valid and infringed, or invalid and not infringed.
This distinction is important for portfolio analysis. A dismissal following settlement is procedurally different from:
- A judgment of noninfringement.
- A judgment of invalidity under 35 U.S.C. §§ 101, 102, 103 or 112.
- A finding of inequitable conduct.
- A final written decision from the Patent Trial and Appeal Board.
- A Federal Circuit decision limiting claim scope.
The case therefore reduced immediate litigation uncertainty but did not generate precedent weakening Actelion’s broader selexipag portfolio.
What was the Orange Book status of Uptravi?
Uptravi’s Orange Book position depended on the patents listed for the approved selexipag product and the timing of patent expiration. Orange Book-listed patents can support a Paragraph IV suit when an ANDA applicant certifies that the listed patent is invalid, unenforceable or not infringed.
The relevant commercial analysis must separate four dates:
| Date type |
Business effect |
| Patent expiration |
Ends the ordinary patent exclusion period for the covered claims. |
| Pediatric exclusivity expiration |
Can add six months to certain listed patent or exclusivity periods. |
| Regulatory exclusivity expiration |
Controls FDA approval timing independently of patent rights. |
| Settlement launch date |
May permit entry before the latest patent expiration. |
The existence of an Orange Book listing does not itself establish that every claim is enforceable or that the listed patent will block a noninfringing product. It does, however, increase the probability of Hatch-Waxman litigation and can delay approval through the statutory stay.
When does selexipag lose exclusivity?
Selexipag exclusivity is layered rather than governed by one date. The earliest compound patents, later formulation or use patents, FDA regulatory exclusivity and any pediatric extension must be analyzed separately.
The core commercial risk is that a generic applicant may enter after the first enforceable patent barrier expires but before later portfolio patents expire. A settlement may also create an agreed launch date that is earlier than the final patent expiration.
Actelion’s strategy in the Mylan case was consistent with lifecycle management: assert more than one patent so that Mylan had to address multiple legal barriers. The strategy does not guarantee exclusion through the last patent date because later patents may be vulnerable to invalidity, narrow claim construction or noninfringement arguments.
How strong was Actelion’s patent estate?
Actelion’s selexipag estate had moderate-to-strong defensive characteristics at the time of the 2020 litigation.
Strengths
- Multiple patents were available for assertion.
- The product was a specialized pulmonary arterial hypertension therapy.
- Selexipag had a defined tablet formulation and chronic-use market.
- The ANDA pathway created a statutory approval stay.
- A settlement could preserve commercial exclusivity without exposing the portfolio to a final invalidity ruling.
Weaknesses
- The case did not test the patents through trial.
- Later-expiring patents are often narrower than basic compound claims.
- Generic applicants can attack claim construction, written description, enablement and obviousness.
- A Paragraph IV challenger can use noninfringement theories based on its specific formulation or labeling.
- The commercial value of each patent depends on the exact ANDA product and proposed label.
The absence of a merits decision preserves Actelion’s litigation position but also leaves the estate’s ultimate enforceability untested.
What generic entry risks existed for Uptravi?
The principal generic entry scenarios were:
Delayed entry under settlement
Mylan could launch on a negotiated date before the final patent expiration. This outcome is common when the branded company seeks to preserve near-term revenue and the generic applicant seeks certainty over approval and launch timing.
Entry after patent expiration
Mylan could wait until the relevant patents expired or until regulatory barriers ended. This would reduce litigation risk but delay revenue capture.
Earlier entry after a successful challenge
Mylan could have pursued approval after prevailing on invalidity, noninfringement or enforceability. No public merits judgment in this case established that outcome.
Contingent launch
The settlement could have tied entry to an earlier generic launch, a court decision in another case or regulatory approval. The public dismissal does not disclose enough detail to identify the operative commercial mechanism.
Which companies challenged Actelion’s selexipag patents?
Mylan was one of the ANDA applicants to challenge Actelion’s Uptravi patent position. The broader competitive field included generic pharmaceutical companies capable of filing ANDAs for selexipag tablets after patent and regulatory barriers permitted approval.
The relevant competitors were not limited to direct branded PAH rivals. Generic competition would have affected:
- Uptravi net sales.
- Actelion and Johnson & Johnson pulmonary hypertension revenue.
- Specialty-pharmacy distribution economics.
- Hospital and specialist prescribing.
- Contract manufacturing and supply arrangements.
- Pricing across the prostacyclin-pathway segment.
A first generic entrant would normally receive a stronger commercial position than later ANDA filers, particularly if eligible for 180-day generic exclusivity under the Hatch-Waxman framework.
How did the case affect commercial exposure?
Uptravi was a high-value specialty product with a concentrated prescriber base and chronic treatment demand. Generic entry would likely have produced a gradual erosion pattern rather than an immediate substitution of all branded volume.
The likely impact depended on:
- Number of approved generic suppliers.
- Whether Mylan received a first-filer position.
- Payer substitution rules.
- Generic tablet dosage strengths.
- Distribution through specialty pharmacies.
- Physician willingness to switch stable patients.
- The settlement launch date.
- Availability of competing PAH products.
A single authorized or first generic may initially produce limited erosion. Multiple approved generics typically accelerate price compression and formulary substitution.
Did the case involve biosimilar risk?
No. Selexipag is a small-molecule drug, not a biologic. Mylan’s challenge proceeded through the ANDA pathway, not the Biologics Price Competition and Innovation Act pathway.
The principal risk was generic substitution, not biosimilar interchangeability. That distinction affects approval standards, patent procedures, exclusivity periods and market-entry dynamics.
What licensing or settlement information is public?
The case was dismissed after the parties resolved the dispute, but the public docket does not provide a complete set of commercially operative settlement terms. There is no basis in the public disposition alone to identify:
- A precise authorized launch date.
- Royalty rates.
- Supply obligations.
- Acceleration clauses.
- Co-exclusive entry rights.
- Mylan’s first-filer status.
- A covenant not to sue on later-issued patents.
The absence of public terms limits precise revenue forecasting. It does not change the procedural conclusion that the litigation ended without a merits adjudication.
How does Actelion v. Mylan compare with a trial loss?
A settlement dismissal is more favorable to the branded company than a final invalidity judgment because it avoids a binding adverse precedent and may preserve the enforceability of the broader portfolio. It is less favorable than a trial victory if the settlement grants generic entry before the last asserted patent expires.
| Outcome |
Effect on Actelion |
| Trial victory |
Strongest legal exclusion, subject to appeal and later challenges |
| Trial loss |
Immediate weakening of the asserted patent barriers |
| Settlement with delayed entry |
Preserves defined exclusivity but may shorten the monopoly period |
| Settlement with early entry |
Reduces litigation uncertainty but accelerates revenue erosion |
| Dismissal without public terms |
Ends the case while leaving commercial consequences opaque |
Key Takeaways
- Actelion sued Mylan in the District of Delaware over an ANDA for generic selexipag tablets.
- The product at issue was Uptravi, used to treat pulmonary arterial hypertension.
- The litigation involved Actelion’s selexipag patent estate, including U.S. Patent Nos. 8,598,227 and 9,273,047.
- The case arose from Mylan’s Paragraph IV patent challenge.
- The parties resolved the dispute and the case was dismissed without a reported trial or merits judgment.
- The public disposition does not establish a precise generic launch date or complete settlement terms.
- No biosimilar pathway was involved; the dispute was a small-molecule Hatch-Waxman case.
- The litigation reduced immediate uncertainty but did not determine the ultimate validity, enforceability or infringement status of the asserted patents.
FAQs About Actelion v. Mylan and Uptravi Patent Litigation
What was Mylan’s product in Actelion v. Mylan?
Mylan’s product was an ANDA-based generic version of selexipag tablets, the active ingredient in Actelion’s Uptravi product.
Was Actelion v. Mylan dismissed with prejudice?
The action was dismissed after settlement. The public case disposition should be consulted for the precise dismissal language and any confidentiality-related limitations.
Did Mylan receive permission to launch generic Uptravi?
The public dismissal confirms resolution but does not, by itself, disclose the complete launch provisions. A precise launch date cannot be inferred solely from the docket dismissal.
Are selexipag patents still relevant after the Mylan settlement?
Yes. A settlement with one ANDA applicant does not automatically eliminate Actelion’s rights against other applicants, later-filed ANDAs or products that fall outside the settlement’s scope.
Is Uptravi exposed to biosimilar competition?
No. Uptravi is a small-molecule selexipag product. Competition proceeds through ANDAs and generic substitution rather than the biosimilar approval framework.
References
-
Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 1:20-cv-00110, U.S. District Court for the District of Delaware, docket materials (2020-2021).
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Congress. (2024). 21 U.S.C. § 355: New drugs. United States Code.
-
U.S. Patent and Trademark Office. (2024). Patent Center: U.S. Patent Nos. 8,598,227 and 9,273,047. U.S. Department of Commerce.
